Use of synthetic vitamin B1 derivative for preparing ophthalmocace medicament

Abstract

The invention relates to the use of benfotiamine (a synthetic derivative of vitamin B1) in preparing drugs for treating diabetic retinopathy, that is, a new clinical indication thereof. Benfotiamine can reduce the formation of 6-phosphofructose and 3-phosphoglyceraldehyde by activating the pentose phosphate pathway, thereby blocking abnormal metabolism pathways including DAG-PKC pathway, aminohexose pathway, polyalcohol pathway and AGEs formation pathway and preventing hyperglycemia-induced damage to retinal capillary endothelial cells. The compound is combined with pharmaceutically-acceptable adjuvant to prepare pharmaceutical preparations suitable for oral intake at a daily dose of 5-100mg, 1-3 times daily.

Description

technical field [0001] The invention relates to the use of a synthetic vitamin B1 derivative benfotiamine in the preparation of eye disease medicines, preferably in the preparation of diabetes-induced retinopathy medicines, belonging to the technical field of medicine. Background technique [0002] Benfotiamine, a fat-soluble derivative of thiamine, is a synthetic vitamin B1 derivative that is slightly soluble in water. Synthesized in Japan in the 1960s, it was gradually used in the treatment of neuropathy, sciatica and other neuropathic pains caused by alcoholism after 1962. Since the 1990s, European scholars have carried out a series of studies on thiamine, especially benfotiamine, in the treatment of diabetes and its complications, and have made significant progress in recent years. The drug has been used in Europe for more than a decade to treat various conditions, including nerve damage associated with diabetes. But the drug has never been formally tested in rigorous ...

AI Technical Summary

Problems solved by technology

But there is no evidence that vitamin B1 itself can prevent diabetic retinopathy

Images